How We Score
The Signal Score is a composite assessment of a CDMO's ability to deliver quality therapeutic products reliably. Every score is grounded in verifiable public data — never surveys, never self-reported metrics. CDMOs cannot pay to influence their score.
Composite Score (0–100)
Each CDMO receives a weighted composite across four pillars. Scores recalculate as new data arrives — typically daily for FDA actions, weekly for EMA, operational, and capacity signals.
Quality Compliance 35%
- FDA 483 observations weighted by subsystem and severity (data integrity = 6×, serious findings = 3×, minor procedural = 0.4×)
- Repeat observations (same site, same regulation within 36 months) weighted 2×
- Warning letters (3-year lookback)
- Inspection classifications (NAI/VAI/OAI)
- Consecutive clean inspection streaks
- EMA GMP certificates (active count, compliance status)
- EMA non-compliance statements (equivalent to OAI)
- MHRA GMP certificates (UK post-Brexit regulatory data)
- FDA + EMA + MHRA blended when multiple exist (weighted by record count)
Operations 25%
- Active program count
- Sponsor diversity (concentration risk)
- Modality breadth and specialization
- Phase advancement ratio
- Clinical trial phase distribution
Financial Stability 20%
- Public vs. private status
- Parent company financial health
- Segment revenue (SEC filings)
- M&A stability
- Regulatory risk (BIOSECURE Act)
Capacity Intelligence 20%
- Facility count and coverage
- Expansion announcements
- Press release patterns
- SEC capacity investment mentions
- Modality breadth as indicator
FDA 483 Citation Subsystems & Severity
The Quality Compliance pillar weights every FDA 483 observation by what kind of issue it is (subsystem) and how serious it is (severity 1–5). Source: FDA's public 483 Citations API. We display FDA's verbatim text on every CDMO profile — we do not paraphrase.
Subsystems — citations land in one of nine buckets via deterministic keyword matching on FDA's published descriptions:
Data Integrity — records, audit trails, ALCOA, electronic records, computer system validation.
Environmental Monitoring — aseptic processing, sterility, particulates, cleanroom controls.
Process Validation — qualification, IQ/OQ/PQ, media fills, cleaning validation.
CAPA — investigations, root cause, deviations, OOS handling.
Laboratory Controls — testing, stability, analytical methods, reference standards.
Equipment & Facilities — calibration, maintenance, utilities, HVAC, water systems.
Documentation & Records — SOPs, batch records, written procedures.
Personnel & Training — competency, gowning, supervision.
Other — citations not matching the eight buckets above (typically device or food regulatory citations).
Severity 1–5 uses a rules-as-floor model. Each subsystem has a deterministic floor (data integrity = 5, environmental monitoring and process validation = 4, CAPA and laboratory controls = 3, the rest = 2). For citations where the floor is below 4 and the inspector's description is long enough to merit nuance, we additionally consult Anthropic's Claude with a tight rubric. Final score is the higher of rules and LLM — Claude can promote, never demote. Tiers in the UI: 5 — Critical, 4 — Serious, 3 — Moderate, 2 — Minor, 1 — Trivial.
Validation — the rubric was tested against a 30-citation manual sample with 93% within-±1 agreement and zero LLM bias. The audit harness reruns whenever the prompt or weight table changes.
Repeat observations — flagged when the same site was previously cited for the same regulation under the same subsystem within the prior 36 months. Repeats are weighted 2× because they signal that prior CAPA failed.
Data Sources
EMA EudraGMDP — GMP certificates, non-compliance statements, and manufacturing authorizations across all EU/EEA member states.
MHRA GMDP — UK GMP certificates and non-compliance statements. Post-Brexit, UK regulatory data is separate from EudraGMDP.
ClinicalTrials.gov — 30,000+ clinical studies cross-referenced to identify CDMO manufacturing relationships.
SEC EDGAR — 10-K, 10-Q, 8-K filings for public CDMO parents. Segment revenue, facility investments, risk factors.
Press Monitoring — Partnerships, expansions, leadership changes, regulatory milestones. Categorized and scored.
How Often Is Data Updated?
| Source | Frequency | Last Refresh |
|---|---|---|
| FDA Inspections | Daily (weekdays) | 2026-07-02 |
| FDA Warning Letters | Daily (weekdays) | 2026-07-04 |
| EMA GMP Certificates | Weekly (Mon & Thu) | — |
| MHRA GMP Certificates | Manual (periodic) | — |
| ClinicalTrials.gov | Weekly (Mon & Thu) | 2026-07-02 |
| SEC EDGAR Filings | Weekly (Mon & Thu) | 2026-07-02 |
| Press Monitoring | Daily | 2026-07-04 |
What We Don't Score
Self-reported capabilities, survey data, marketing materials, paid directory listings. If it can't be independently verified, it doesn't enter the model.
Score Statuses
Scored — Full composite across all pillars. Requires quality or operational pillar data and sufficient signals for a composite score.
Partial — Scored on 2-3 pillars. Typically missing financial or capacity data. Score shown as "Partial" on CDMO profiles.
Profiled — CDMO profile with modalities and basic data. Scoring data is being gathered.
CDMO Types
Pure CDMO — Dedicated contract manufacturers whose primary business is manufacturing for sponsors.
Hybrid — Companies with both internal pipelines and contract manufacturing arms (e.g., Novartis, Oxford Biomedica).
Platform — Technology platform providers that enable or automate manufacturing (e.g., Cellares, MaxCyte).
Reagent/Material Supplier — GMP reagent, media, or materials suppliers critical to biopharma manufacturing.
National Center — Government-backed or non-profit manufacturing centers (e.g., Cell and Gene Therapy Catapult, CCRM).
Browse CDMO Landscapes by Modality
Frequently Asked Questions
How does CDMO Signal score CDMOs?
CDMO Signal uses a 4-pillar model: Quality Compliance (35%, FDA inspection data), Operations (25%, ClinicalTrials.gov), Financial Stability (20%, SEC filings), and Capacity Intelligence (20%, press and job-posting signals). All scores are based on publicly verifiable data.
What data sources does CDMO Signal use?
Five primary sources: the FDA Data Dashboard for inspections, 483 citations, and warning letters; EMA EudraGMDP and MHRA GMDP for GMP certificates; ClinicalTrials.gov for program cross-referencing; and SEC EDGAR for financial filings of public CDMO parents.
Can CDMOs pay to influence their Signal Score?
No. Scores are based exclusively on publicly available, independently verifiable data. CDMOs cannot pay for higher scores, featured placement, or removal of negative findings. The methodology is fully transparent and published on this page.
How many CDMOs does CDMO Signal track?
CDMO Signal currently tracks 237 CDMOs globally, scored on independent FDA, EMA/MHRA, clinical-trial, financial, and capacity data. Coverage expands continuously, and you can request a lookup for any CDMO not yet listed.
What is a CDMO?
A CDMO (contract development and manufacturing organization) develops and manufactures drug products for other companies — handling process development, GMP production, and regulatory support so sponsors don't have to build their own facilities.
What's the difference between a CDMO and a CMO?
A CMO (contract manufacturing organization) only manufactures; a CDMO adds development services — process and formulation development, analytical method development, and scale-up — alongside GMP manufacturing.
How do I choose a CDMO?
Compare CDMOs on regulatory track record (FDA inspections, EMA/MHRA GMP), relevant modality experience, capacity and timelines, and financial stability. CDMO Signal ranks CDMOs on these factors — start from a modality landscape page or search by name.